These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21761954)

  • 1. Guidelines and best practices for appropriate use of dalfampridine in managed care populations.
    Miravalle AA
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S154-60. PubMed ID: 21761954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
    Berger JR
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving quality of life in multiple sclerosis: an unmet need.
    Zwibel HL; Smrtka J
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S139-45. PubMed ID: 21761952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalfampridine prior authorization program: a cohort study.
    Gleason PP; Phillips J; Fenrick BA; Delgado-Riley A; Starner CI
    J Manag Care Pharm; 2013; 19(1):18-25. PubMed ID: 23383704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will the newer oral MS agents be welcomed by managed care organizations?
    Lipsy RJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S227-33. PubMed ID: 20873947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.
    Panitch H; Applebee A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1511-21. PubMed ID: 21635193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.
    Owens GM; Olvey EL; Skrepnek GH; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S41-53. PubMed ID: 23383732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
    Pikoulas TE; Fuller MA
    Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
    Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing dalfampridine efficacy in the physician's office.
    Raffel JB; Malik O; Nicholas RS
    Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of impaired mobility to patient burden in multiple sclerosis.
    Sutliff MH
    Curr Med Res Opin; 2010 Jan; 26(1):109-19. PubMed ID: 19916707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis.
    Brandes DW; Shaya FT; Pill MW
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S171-7. PubMed ID: 20615053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gait disorders in multiple sclerosis.
    Bethoux F
    Continuum (Minneap Minn); 2013 Aug; 19(4 Multiple Sclerosis):1007-22. PubMed ID: 23917098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.